文献速递瓣膜外科

微创二尖瓣手术后再次二尖瓣手术的早期与远期结局

Early and long-term outcomes following redo mitral valve surgery in patients with prior minimally invasive mitral valve surgery.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2024-01-01

本研究纳入2002年1月至2021年12月间既往接受微创二尖瓣手术后行再次二尖瓣手术的187例患者,前瞻性收集数据并回顾性分析。30天死亡率为6.4%(12/187),5年和12年估计生存率分别为61.8%和38.3%。术前卒中及感染性心内膜炎是远期死亡的独立预测因素。

要点

  • 再次二尖瓣手术30天死亡率为6.4%(12/187),早期围术期死亡率低。
  • 5年和12年估计生存率分别为61.8%和38.3%。
  • 术前卒中(HR 3.28,95%CI 1.37-7.85,P=0.007)和感染性心内膜炎(HR 1.85,95%CI 1.09-3.11,P=0.021)是远期死亡的独立预测因素。

核心结论

  • 既往微创二尖瓣手术后行再次二尖瓣手术可安全实施,早期围术期死亡率低,远期生存率可接受。
  • 术前卒中、感染性心内膜炎及同期三尖瓣手术是远期死亡的独立预测因素。

研究设计与样本

  • 纳入2002年1月至2021年12月间既往接受微创二尖瓣手术后行再次二尖瓣手术的患者187例,研究数据前瞻性收集并回顾性分析。
  • 主要结局为30天死亡率和远期生存率。

主要发现

  • 187例患者中,34例(18.2%)行再次二尖瓣修复,153例(81.8%)行二尖瓣置换。
  • 中位年龄66岁(四分位距56-74),女性80例(42.8%)。
  • 再次二尖瓣手术经正中胸骨切开169例(90.4%),77例(41.2%)行额外同期手术。
  • 中位重症监护室停留时间1天(1-5)。
  • 30天死亡率为6.4%(12/187),5年和12年估计生存率分别为61.8%和38.3%。

关键数值与推荐

  • 术前卒中:风险比(HR)3.28,95%置信区间(CI)1.37-7.85,P=0.007,为远期死亡的独立预测因素。
  • 感染性心内膜炎:HR 1.85,95%CI 1.09-3.11,P=0.021,为远期死亡的独立预测因素。
  • 同期三尖瓣手术为远期死亡的独立预测因素(原文未报告具体效应值)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The frequency of minimally invasive mitral valve surgery (MVS) has steadily increased over the last decades and therefore surgeons are now encountering an increasing number of patients requiring mitral valve (MV) reoperations post-minimally invasive MVS. The aim of this study was to analyse the early postoperative outcomes and the long-term survival in patients who undergo reoperative MVS following previous minimally invasive surgery. METHODS: Patients who underwent redo MVS following prior minimally invasive MVS between January 2002 and December 2021 were included in our analysis. Study data were prospectively collected and retrospectively analysed. The primary outcomes were 30-day mortality and long-term survival. RESULTS: Among the 187 included patients, 34 (18.2%) underwent repeat MV repair and 153 (81.8%) MV replacement. The median age was 66 years (interquartile range 56-74) and 80 (42.8%) patients were female. Redo MVS was performed through median sternotomy in 169 patients (90.4%). A total of 77 (41.2%) patients had additional concomitant procedures. The median intensive care unit stay was 1 day (1-5). The 30-day mortality was 6.4% (12/187). Estimated survival at 5 and 12 years was 61.8% and 38.3%, respectively. Preoperative stroke (hazard ratio 3.28, 95% confidence interval 1.37-7.85, P = 0.007) as well as infective endocarditis (hazard ratio 1.85; 95% confidence interval 1.09-3.11, P = 0.021) were independent predictors of long-term mortality. CONCLUSIONS: Redo MVS following prior minimally invasive MVS can be performed safely with low early perioperative mortality and acceptable long-term survival. Preoperative stroke, infective endocarditis and concomitant tricuspid valve surgery are independent predictors of long-term mortality.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Schumacher K, Marin Cuartas M, de la Cuesta M, et al. Early and long-term outcomes following redo mitral valve surgery in patients with prior minimally invasive mitral valve surgery. Interdiscip Cardiovasc Thorac Surg. 2024. PMID: 38498841. doi:10.1093/icvts/ivae042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。